Fig. 4: Kinetics of anti-SARS-COV-2-IgG antibodies in eight participants with evidence of breakthrough infection in the Nigerian cohort.
From: SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
a–g including one (h) with evidence of breakthrough infection and re-infection with SARS-COV-2 reinfection following evidence of positive IgG anti-N at baseline; negative IgG anti-N at 1 month after second dose and positive IgG anti-N 3 months post-second dose. Binding antibodies to Wu-1 and Omicron BA.1 are shown.
